Growth in homozygous beta-thalassemia after bone marrow transplantation.

abstract：:MSCs are multipotent cells that can be isolated from several human tissues and expanded ex vivo for clinical use. They comprise a heterogeneous population of cells, which, through production of growth factors, cell-to-cell interactions and secretion of matrix proteins, has a role in the regulation of hematopoiesis. In...

journal_title：Bone marrow transplantation

authors： Bernardo ME,Cometa AM,Locatelli F

更新日期：2012-03-01 00:00:00

abstract：:We review here the functional and kinetic characteristics of highly purified hematopoietic CD34+ mobilized into peripheral blood (PB) by granulocyte colony-stimulating factor (G-CSF) with or without chemotherapy for autologous or allogeneic transplantation. Circulating CD34+ cells were evaluated for their colony-formi...

journal_title：Bone marrow transplantation

authors： Lemoli RM,Tafuri A,Fortuna A,Catani L,Rondelli D,Ratta M,Tura S

更新日期：1998-12-01 00:00:00

abstract：:HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

journal_title：Bone marrow transplantation

authors： Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

更新日期：2007-07-01 00:00:00

abstract：:Fentanyl is a synthetic opioid that can be delivered through a transdermal therapeutic system (TTS). The aim of this study was to assess the efficacy of fentanyl TTS in treating oral mucositis pain in 75 adult hematopoietic stem cell transplant (HSCT) patients. The analysis was based on 62 patients who developed mucos...

journal_title：Bone marrow transplantation

authors： Demarosi F,Lodi G,Soligo D,Sardella A,Volpe AD,Carrassi A,Deliliers GL

更新日期：2004-06-01 00:00:00

abstract：:Historically, the mortality of patients admitted to the ICU after allogeneic stem cell transplantation (alloSCT) is high. Advancements in transplantation procedures, infectious monitoring and supportive care may have improved the outcome. This study aimed to determine short-term and long-term mortality after ICU admis...

journal_title：Bone marrow transplantation

authors： van der Heiden PLJ,Arbous MS,van Beers EJ,van den Bergh WM,le Cessie S,Demandt AMP,Eefting M,Hess C,Kusadasi N,Marijt WAF,van Mook WNKA,Müller MCA,Tuinman PR,van Vliet M,van Westerloo DJ,Blijlevens NMA,HEMA-ICU Study Grou

更新日期：2019-03-01 00:00:00

abstract：:We conducted a prospective randomized clinical trial to assess the mobilizing efficacy of filgrastim, lenograstim and molgramostim following a disease-specific chemotherapy regimen. Mobilization consisted of high-dose cyclophosphamide in 45 cases (44%), and cisplatin/ifosfamide/etoposide or vinblastine in 22 (21%), fo...

journal_title：Bone marrow transplantation

authors： Kopf B,De Giorgi U,Vertogen B,Monti G,Molinari A,Turci D,Dazzi C,Leoni M,Tienghi A,Cariello A,Argnani M,Frassineti L,Scarpi E,Rosti G,Marangolo M

更新日期：2006-09-01 00:00:00

abstract：:The era of reduced-intensity allogeneic stem cell transplantation, with its emphasis on older patients, has created new challenges in the management of what is now an older related stem cell donor population. These donors are now on average no less than 10 years older than in the mid-1990s. Donors over 70 years of age...

journal_title：Bone marrow transplantation

authors： Anderlini P

更新日期：2017-01-01 00:00:00

abstract：:Several high-dose therapy regimens are used for autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed and refractory Hodgkin's lymphoma (HL) with variable disease response. An intensified regimen of etoposide (VP-16) 2,400 mg/m(2), cyclophosphamide 7,200 mg/m(2) and carmustine (BCNU) 600 mg/m(2) ...

journal_title：Bone marrow transplantation

authors： Benekli M,Smiley SL,Younis T,Czuczman MS,Hernandez-Ilizaliturri F,Bambach B,Battiwalla M,Padmanabhan S,McCarthy PL Jr,Hahn T

更新日期：2008-04-01 00:00:00

abstract：:Neutrophil and platelet engraftment times are significantly shorter in patients undergoing PBPCT compared with ABMT. The explanation for this is unclear. The reticulated platelet percentage (RP%) has been established as a measure of bone marrow platelet production. Using this measurement we have followed thrombopoiesi...

journal_title：Bone marrow transplantation

authors： Richards EM,Jestice HK,Mahendra P,Scott MA,Marcus RE,Baglin TP

更新日期：1996-06-01 00:00:00

abstract：:The role of autologous bone marrow transplantation in the treatment of malignant disease is currently being evaluated. The peripheral blood represents an alternative source of haemopoietic progenitors and the use of circulating rather than bone marrow stem cells permits autografting in patients with infiltrated bone m...

journal_title：Bone marrow transplantation

authors： Bell AJ,Hamblin TJ,Oscier DG

更新日期：1986-12-01 00:00:00

abstract：:From May 1985 to July 1989, 76 patients with leukemia (30 acute myelogenous leukemia, 24 acute lymphoblastic leukemia and 22 chronic myeloid leukemia) were randomized to receive either cyclosporin (CSP) alone (n = 39) or CSP combined with methotrexate (CSP + MTX, n = 37) for graft-versus-host disease (GVHD) prophylaxi...

journal_title：Bone marrow transplantation

authors： Mrsić M,Labar B,Bogdanić V,Nemet D,Pavletić Z,Plavsić F,Dobrić I,Marusić M,Francetić I,Kastelan A

更新日期：1990-08-01 00:00:00

abstract：:One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma. While this observation has largely been made in patients under the age of 65 years, there is evidence to suggest that the conclusions can be extrapolate...

journal_title：Bone marrow transplantation

authors： Mehta J,Singhal S

更新日期：2007-12-01 00:00:00

abstract：:The use of hematopoietic stem cells for in utero transplantation to create permanent hematochimerism represents a new concept in fetal therapy, although this approach has provided heterogeneous results. In this paper we have undertaken molecular, phenotypic and functional studies aimed at identifying the presence of f...

journal_title：Bone marrow transplantation

authors： Renda MC,Fecarotta E,Dieli F,Markling L,Westgren M,Damiani G,Jakil C,Picciotto F,Maggio A

更新日期：2000-01-01 00:00:00

abstract：:Abnormalities in liver function tests are common in hematopoietic SCT (HSCT) recipients. We retrospectively investigated the role of liver biopsy in determining the cause of elevated liver enzymes and its impact on the management of patients in the post-HSCT setting. A total of 24 consecutive liver biopsies were obtai...

journal_title：Bone marrow transplantation

authors： Sucak GT,Yegin ZA,Ozkurt ZN,Aki SZ,Karakan T,Akyol G

更新日期：2008-10-01 00:00:00

abstract：:The aim of this study was to compare anxiety, pain and discomfort of cancer patients submitted to either peripheral blood progenitor cell collection (PBPCC) or bone marrow harvest (BMH). Patients, randomized (7/1993-2/1994), in view of autograft, to receive the first procedure or the second one, completed self-adminis...

journal_title：Bone marrow transplantation

authors： Auquier P,Macquart-Moulin G,Moatti JP,Blache JL,Novakovitch G,Blaise D,Faucher C,Viens P,Maraninchi D

更新日期：1995-10-01 00:00:00

abstract：:Graft failure is a major concern after cord blood transplantation (CBT) or HLA-haploidentical transplantation (haplo-SCT). As patients who undergo CBT or haplo-SCT almost always lack both matched-related and -unrelated donors, salvage transplantation would also be limited to either CBT or haplo-SCT. In this study, we ...

journal_title：Bone marrow transplantation

authors： Yoshihara S,Ikegame K,Taniguchi K,Kaida K,Kim EH,Nakata J,Kato R,Inoue T,Fujioka T,Tamaki H,Okada M,Soma T,Ogawa H

更新日期：2012-03-01 00:00:00

abstract：:The aim of this retrospective study was to determine the incidence and the clinical outcome of secondary oral cancer (SOC) and to assess potential risk factors in a large cohort of patients (n = 908), who received allogeneic hemopoietic cell transplantation (HCT) either for a malignant (n = 733) or nonmalignant hemato...

journal_title：Bone marrow transplantation

authors： Santarone S,Natale A,Angelini S,Papalinetti G,Vaddinelli D,Di Bartolomeo A,Di Bartolomeo P

更新日期：2020-11-24 00:00:00

abstract：:Genetic mutations of proteins regulating nuclear factor of kappa-light polypeptide gene enhancer in B lymphocyte (NF-kappaB) activation result in heritable diseases of development and immunity. Hypomorphic, X-linked mutations in the IKBKG gene (NF-kappaB essential modulator (NEMO) protein), and hypermorphic, autosomal...

journal_title：Bone marrow transplantation

authors： Fish JD,Duerst RE,Gelfand EW,Orange JS,Bunin N

更新日期：2009-02-01 00:00:00

abstract：:The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medi...

journal_title：Bone marrow transplantation

authors： Pillay B,Lee SJ,Katona L,De Bono S,Warren N,Fletcher J,Burney S

更新日期：2012-10-01 00:00:00

abstract：:Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

journal_title：Bone marrow transplantation

authors： Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

更新日期：2016-01-01 00:00:00

abstract：:We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

更新日期：2008-03-01 00:00:00

abstract：:We report long-term results of high-dose cyclophosphamide, etoposide and carboplatin with ABMT in 20 patients with metastatic breast cancer. Median age of the group was 41 years, ECOG performance status = 0 in 18 patients and 1 in two patients. Twelve patients had received adjuvant chemotherapy. Predominant sites of m...

journal_title：Bone marrow transplantation

authors： Baker WJ,Vukelja SJ,Burrell LM,Lee N,Perry JJ

更新日期：1998-04-01 00:00:00

abstract：:We recently reported that adolescents and young adults (AYAs) with B-cell ALL receiving allogeneic hematopoietic cell transplantation (allo-HCT) have inferior survival compared with children, primarily because of greater TRM. We therefore hypothesized that in the setting of allo-HCT for AML, similar inferior outcomes ...

journal_title：Bone marrow transplantation

authors： Burke MJ,Gossai N,Cao Q,Macmillan ML,Warlick E,Verneris MR

更新日期：2014-02-01 00:00:00

abstract：:Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late ...

journal_title：Bone marrow transplantation

authors： Freytes CO,Lazarus HM

更新日期：2009-11-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:Seventy-one mobilised PBSC collections were subject to CD34+ cell purification using the CEPRATE SC stem cell concentration system. The overall median purity of CD34+ cells was 69% (6-93%). CD34+ cell, and GM-CFC recoveries were 52% (8-107%) and 36% (3-118%). Purity was logarithmically related to the input percentage ...

journal_title：Bone marrow transplantation

authors： Watts MJ,Sullivan AM,Ings SJ,Leverett D,Peniket AJ,Perry AR,Williams CD,Devereux S,Goldstone AH,Linch DC

更新日期：1997-07-01 00:00:00

abstract：:The purpose of the study was to assess the toxicity and efficacy of an oral, combination antiemetic regimen including granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA, USA) in the setting of highly emetogenic conditioning chemotherapy for stem cell transplantation. Antiemetic prophylaxis consi...

journal_title：Bone marrow transplantation

authors： Frakes LA,Brehm TL,Kosty MP,Miller WE,McMillan RL,Mason J,Meisenberg BR

更新日期：1997-09-01 00:00:00

abstract：:To evaluate whether conditions for adapted dose mafosfamide (mafo) purging vary with accumulating chemotherapy, we studied the sensitivity of bone marrow CFU-GM in a total of 30 patients at different stages of treatment. We determined the dose of 95% CFU-GM growth-inhibition by mafo (ID95) in 23 patients with acute my...

journal_title：Bone marrow transplantation

authors： Martin H,Bruecher J,Claudé R,Hoelzer D

更新日期：1993-11-01 00:00:00

abstract：:Donor-recipient sex incompatibility has been associated with transplant outcomes in allogeneic hematopoietic SCT. Such outcomes might be because mHA encoded by Y chromosome genes could be immunological targets for allogeneic T cells and B cells to induce GVHD, GVL effect and graft failure. However, its effect on the o...

journal_title：Bone marrow transplantation

authors： Konuma T,Kato S,Ooi J,Oiwa-Monna M,Ebihara Y,Mochizuki S,Yuji K,Ohno N,Kawamata T,Jo N,Yokoyama K,Uchimaru K,Tojo A,Takahashi S

更新日期：2014-05-01 00:00:00

abstract：:Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using...

journal_title：Bone marrow transplantation

authors： Bashey A,Solomon SR

更新日期：2014-08-01 00:00:00